SCHEMBL8937523

SCHEMBL8937523

COc1ccc(/C(=C/C(=O)N2CCN(C(=O)c3cc(OC)c(OC)c(OC)c3)CC2)c2cc(Cl)ccc2Cl)cc1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
LMNA P02545 2/20 0.59
CYP3A4 P08684 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
CYP1A2 P05177 1/20 0.49
GPR183 P32249 2/20 0.48
POLB P06746 1/20 0.47
MGLL Q99685 1/20 0.45
GAA P10253 1/20 0.45
F10 P00742 1/20 0.44
TP53 P04637 1/20 0.44
HSD17B10 Q99714 1/20 0.44
PKM P14618 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937599 1.00 ALDH1A1 (0.62) ALDH1A1L3MBTL1LMNACYP3A4CYP2C9
SCHEMBL8937526 1.00 ALDH1A1 (0.62) ALDH1A1L3MBTL1LMNACYP3A4CYP2C9
SCHEMBL8937337 0.92 ALDH1A1 (0.62) ALDH1A1L3MBTL1LMNACYP3A4CYP2C9
SCHEMBL8937332 0.92 ALDH1A1 (0.62) ALDH1A1L3MBTL1LMNACYP3A4CYP2C9
SCHEMBL8937649 0.92 LMNA (0.55) ALDH1A1L3MBTL1LMNACYP3A4CYP2C9
SCHEMBL8937653 0.92 LMNA (0.55) ALDH1A1L3MBTL1LMNACYP3A4CYP2C9
SCHEMBL8937637 0.89 ALDH1A1 (0.64) ALDH1A1L3MBTL1LMNACYP3A4CYP2C9
SCHEMBL8937500 0.89 ALDH1A1 (0.64) ALDH1A1L3MBTL1LMNACYP3A4CYP2C9
SCHEMBL8937498 0.89 ALDH1A1 (0.64) ALDH1A1L3MBTL1LMNACYP3A4CYP2C9
SCHEMBL8937275 0.87 ALDH1A1 (0.66) ALDH1A1L3MBTL1LMNACYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US claimed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US claimed
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed